CRISPR Therapeutics Analyst Ratings
BenzingaApr 19 00:10
Needham: Reiterated CRISPR Therapeutics (CRSP.US) rating, adjusted from buy to buy rating, target price of $90.00.
Zhitong FinanceApr 11 18:40
CRISPR Therapeutics Analyst Ratings
BenzingaApr 11 18:37
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target
BenzingaApr 11 18:38
CRISPR Therapeutics Analyst Ratings
BenzingaMar 6 21:09
Mizuho Maintains Buy on CRISPR Therapeutics, Raises Price Target to $99
BenzingaMar 6 21:09
Crispr Therapeutics AG (CRSP) Receives a Buy From Truist Financial
TipRanksFeb 27 20:47
Damo: The CRISPR Therapeutics (CRSP.US) holdings reduction rating was maintained, and the target price was adjusted from $46.00 to $48.00.
Zhitong FinanceFeb 26 23:51
CRISPR Therapeutics Analyst Ratings
BenzingaFeb 26 23:45
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating
MT NewswiresFeb 22 23:46
CRISPR Therapeutics Analyst Ratings
BenzingaFeb 22 23:41
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept
MT NewswiresFeb 22 20:07
Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $112
BenzingaFeb 22 18:44
CRISPR Therapeutics Analyst Ratings
BenzingaFeb 22 00:39
CRISPR Therapeutics Analyst Ratings
BenzingaFeb 15 19:56
Truist Cuts CRISPR Therapeutics Target to $120 From $160
InvestingFeb 8 04:32
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Crispr Therapeutics AG (CRSP) and Gilead Sciences (GILD)
TipRanksJan 24 14:53
Crispr Therapeutics AG: Maintained Buy Rating With Adjusted Price Target Following FDA Approval and Strategic Pipeline Prioritization
TipRanksJan 24 14:26
Crispr Therapeutics AG (CRSP) Receives a Buy From Oppenheimer
TipRanksJan 23 02:09
Hold Rating on Crispr Therapeutics AG Amid Promising Programs and Market Strategy Considerations
TipRanksJan 12 18:49
No Data
No Data